Compare TIMB & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIMB | QGEN |
|---|---|---|
| Founded | 1998 | 1986 |
| Country | Brazil | Netherlands |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 10.2B |
| IPO Year | 2020 | 1998 |
| Metric | TIMB | QGEN |
|---|---|---|
| Price | $25.47 | $38.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $23.38 | ★ $51.30 |
| AVG Volume (30 Days) | 366.7K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.81% | 6.07% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.11 | $8.18 |
| Revenue Next Year | $5.31 | $5.66 |
| P/E Ratio | ★ $15.81 | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.18 | $38.13 |
| 52 Week High | $27.74 | $57.82 |
| Indicator | TIMB | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 26.41 |
| Support Level | $24.63 | N/A |
| Resistance Level | $27.66 | $49.11 |
| Average True Range (ATR) | 0.60 | 0.96 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 48.07 | 3.11 |
TIM, which is 67%-owned by Telecom Italia, is the third largest wireless carrier in Brazil, with 62 million subscribers, equal to about 23% of the market. The firm owns 49% of I-Systems, an infrastructure partnership that is expanding its network footprint across Brazil. I-Systems can provide broadband service to about 8 million locations, including 6.5 million with fiber, equal to 10%-15% of the country. TIM leases capacity on the venture's network to serve retail broadband customers under the UltraFibra brand, but it has agreed to buy out its joint venture partner in 2026, taking full ownership of these assets. TIM also resells fiber network access from other providers.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).